ArticleMolecular psychiatry2011
Identification of blood biomarkers for psychosis using convergent functional genomics.
Article in Molecular psychiatry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 2 syntheses or guidelines pooled it, 162 citations in OpenAlex.
- Up-Regulation of S100 Gene Family in Brain Samples of a Subgroup of Individuals with Schizophrenia: Meta-analysis.Neuromolecular medicine · 2023Pooled it
- Common variants at VRK2 and TCF4 conferring risk of schizophrenia.Human molecular genetics · 2011Pooled it
- Acute psilocin increased cortical activity in rat.Frontiers in neuroscience · 2026Article
- Next-generation precision medicine for suicidality prevention.Translational psychiatry · 2024Article
- Age, sex, and apolipoprotein E isoform alter contextual fear learning, neuronal activation, and baseline DNA damage in the hippocampus.Molecular psychiatry · 2023Article
- Identification of immune-related biomarkers in peripheral blood of schizophrenia using bioinformatic methods and machine learning algorithms.Frontiers in cellular neuroscience · 2023Article
- Sex linked behavioral and hippocampal transcriptomic changes in mice with cell-type specificFrontiers in neuroscience · 2023Article
- Acute psilocybin increased cortical activities in rats.Frontiers in neuroscience · 2023Article
- Changes in the Brain Extracellular Matrix Composition in schizophrenia: A Pathophysiological Dysregulation and a Potential Therapeutic Target.Cellular and molecular neurobiology · 2022Article
- Systems-Level Analysis of Genetic Variants Reveals Functional and Spatiotemporal Context in Treatment-resistant Schizophrenia.Molecular neurobiology · 2022Article
- Categorical versus dimensional models of early psychosis.Early intervention in psychiatry · 2022Article
- Clinical, pathological and genetic characteristics of Perry disease-new cases and literature review.European journal of neurology · 2021Review
- The Etiology of Auditory Hallucinations in Schizophrenia: From Multidimensional Levels.Frontiers in neuroscience · 2021Review
- Integrative In Silico Analysis of Genome-Wide DNA Methylation Profiles in Schizophrenia.Journal of molecular neuroscience : MN · 2020Article
- Modulation of cognition and neuronal plasticity in gain- and loss-of-function mouse models of the schizophrenia risk gene Tcf4.Translational psychiatry · 2020Article
- Convergent Functional Genomics approach to prioritize molecular targets of risk in early life stress-related psychiatric disorders.Brain, behavior, & immunity - health · 2020Review
- The Role of Brain Microvascular Endothelial Cell and Blood-Brain Barrier Dysfunction in Schizophrenia.Complex psychiatry · 2020Review
- Blood biomarkers for memory: toward early detection of risk for Alzheimer disease, pharmacogenomics, and repurposed drugs.Molecular psychiatry · 2020Article
- A Novel CosegregatingGenes · 2020Article
- Gene expression changes associated with trajectories of psychopathology in a longitudinal cohort of children and adolescents.Translational psychiatry · 2020Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 1 country.
Funding
Abstract
There are to date no objective clinical laboratory blood tests for psychotic disease states. We provide proof of principle for a convergent functional genomics (CFG) approach to help identify and prioritize blood biomarkers for two key psychotic symptoms, one sensory (hallucinations) and one cognitive (delusions). We used gene expression profiling in whole blood samples from patients with schizophrenia and related disorders, with phenotypic information collected at the time of blood draw, then cross-matched the data with other human and animal model lines of evidence. Topping our list of candidate blood biomarkers for hallucinations, we have four genes decreased in expression in high hallucinations states (Fn1, Rhobtb3, Aldh1l1, Mpp3), and three genes increased in high hallucinations states (Arhgef9, Phlda1, S100a6). All of these genes have prior evidence of differential expression in schizophrenia patients. At the top of our list of candidate blood biomarkers for delusions, we have 15 genes decreased in expression in high delusions states (such as Drd2, Apoe, Scamp1, Fn1, Idh1, Aldh1l1), and 16 genes increased in high delusions states (such as Nrg1, Egr1, Pvalb, Dctn1, Nmt1, Tob2). Twenty-five of these genes have prior evidence of differential expression in schizophrenia patients. Predictive scores, based on panels of top candidate biomarkers, show good sensitivity and negative predictive value for detecting high psychosis states in the original cohort as well as in three additional cohorts. These results have implications for the development of objective laboratory tests to measure illness severity and response to treatment in devastating disorders such as schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.